Press Releases September 9, 2026 02:00 AM

Pharming Group to participate in September investor conferences

Pharming Group to present at major September investor conferences in New York

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
PHAR

Pharming Group N.V., a global biopharmaceutical company listed on Euronext Amsterdam and Nasdaq, announced its participation in two major investor conferences in September 2026: the H.C. Wainwright 28th Annual Global Investment Conference and the Morgan Stanley 24th Annual Global Healthcare Conference, both held in New York. CEO Fabrice Chouraqui will present live, with webcasts available for investors. The company focuses on developing innovative medicines for rare and life-threatening diseases.

Pharming Group to participate in September investor conferences
PHAR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Pharming Group is participating in two prominent healthcare investor conferences in September 2026.
  • The CEO will deliver presentations and engage with investors both live and via webcast.
  • Pharming's focus includes innovative treatments for rare and debilitating diseases, highlighting its role in biopharmaceutical innovation.

Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the month of September:

  • H.C. Wainwright 28th Annual Global Investment Conference, New York, September 14, 2026
    Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 14 at 09:30 EDT/15:30 CEST. A live webcast and replay of the presentation will be made available in the “Events and presentations” and “Our news” sections of Pharming’s website.
  • Morgan Stanley 24th Annual Global Healthcare Conference, New York, September 15, 2026

For more information about these conferences, or to schedule a one-on-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at [email protected] or your H.C. Wainwright or Morgan Stanley representative.

About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:
Pharming
Michael Levitan, VP Investor Relations & Capital Markets 
T: +1 (908) 705 1696 
E: [email protected] 

Saskia Mehring, Head of Corporate Communications 
T: +31 6 28 32 60 41 
E: [email protected] 

Media Relations 
Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming)
E: [email protected]

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming) 
T: +31 6 53 81 64 27 

Attachment

  • Pharming attending Investor Conferences September 2026_EN_09SEP26

Risks

  • No new product or financial updates provided in this announcement, limiting immediate impact on investment decisions.
  • Investor participation and investor interest at these conferences are uncertain and may not translate into positive stock movement.
  • Broader market conditions and healthcare sector dynamics could overshadow the potential benefits of these presentations.

More from Press Releases

Zscaler launches Agentic SOC to contain AI-Driven Threats Sep 9, 2026 Launch of StoneX Trading marks a new era for City Index Sep 9, 2026 MulticoreWare and Micware Sign MOU to Explore Potential Collaboration in ADAS Performance Optimization and Physical AI at the Edge Sep 9, 2026 California Water Service Kicks Off Back-to-School Season With 13th Year of Tap Into Learning Program Sep 8, 2026 XORTX Re-Engages Investor Relations Program Sep 8, 2026